Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis  Moussab.

Slides:



Advertisements
Similar presentations
What We Talk About When We Talk About Fat Evan D. Rosen, Bruce M. Spiegelman Cell Volume 156, Issue 1, Pages (January 2014) DOI: /j.cell
Advertisements

E2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in Locally Extensive and Advanced Stage Hodgkin Lymphoma (HL) Gordon LI, et al. ECOG 2496, J Clin Oncol.
 Aromatase inhibitors act by lowering estrogen in the circulation and in tumor cells in post- menopausal women.
Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled.
Volume 13, Issue 6, Pages (June 2013)
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group  Fernando Franco Pérez, Javier Lavernia, David Aguiar-Bujanda, José.
A-I. MD Anderson Cancer Center algorithms for Hodgkin lymphoma
Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma  Jennifer L. Herrmann, Naveed Sami 
Clinical Lymphoma, Myeloma and Leukemia
The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma  Kyung Ah Yoh, Ho Sup Lee,
A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis  Meletios Athanasios.
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group  Fernando Franco Pérez, Javier Lavernia, David Aguiar-Bujanda, José.
VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study 
Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry ( )  Sundar Jagannath, Rafat Abonour, Brian.
Current Therapy for Multiple Myeloma
Nishitha M. Reddy, Olalekan Oluwole, John P. Greer, Brian G
Yuji Nakamoto  Clinical Lymphoma, Myeloma and Leukemia 
Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data  Kathleen Lang,
An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic.
The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient.
Moderate Dose Escalation for Advanced Stage Hodgkin’s Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine,
Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma,
Hereditary Hemochromatosis Manifesting After Treatment of Paroxysmal Nocturnal Hemoglobinuria With Eculizumab  Elizabeth Elliott, Salman Waheed, Sahr.
Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics  Vincent T. Ma, Philip S. Boonstra,
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care.
Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission  Quoc Truong,
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.
A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B- cell Non-Hodgkin Lymphoma  Pallawi Torka, Priyank Patel, Wei Tan,
Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective,
Stem Cell Therapies in Clinical Trials: Progress and Challenges
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p  Sandy W. Wong, Ute Hegenbart, Giovanni Palladini,
A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML  Benyam Muluneh, Kaitlyn Buhlinger,
Subepithelial Corneal Immunoglobulin Deposition as a Manifestation of Multiple Myeloma: A Case Report and Literature Review  Trent P. Wang, Steven G.
Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience  AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world.
Gordon LI et al. Proc ASH 2010;Abstract 415.
Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study  Rena Buckstein,
Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma  Shumaila.
Targeting T Cell Co-receptors for Cancer Therapy
Genetic Mutations in B-Acute Lymphoblastic Leukemia Among African American and European American Children  Amit Reddy, Ingrid Espinoza, Dana Cole, Jason.
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma  John M. Burke,
Vertebral Fracture Risk of Multiple Myeloma Assessed by a CT-based Finite Element and Trabecular Structure Analysis  Miyuki Takasu, Yoko Kaichi, Kazuo.
Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature 
Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma
Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV- associated Non-Hodgkin's Lymphoma (AMC-075)  Juan C. Ramos, Joseph A. Sparano,
Clinical Lymphoma, Myeloma and Leukemia
Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data  Preetesh Jain, Hagop Kantarjian,
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I  Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa,
Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides  Francine Foss, Madeleine Duvic, Adam Lerner, Joel Waksman, Sean Whittaker 
Advances in ICD Therapy
A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.
Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid.
A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic.
Volume 19, Issue 10, Pages (October 2018)
Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson 
Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration  Julio.
Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience  Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,
Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice  Abdalla Awidi, Salah Abbasi,
Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review  Jill A. Bell, Aaron.
Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma  Stephen.
Effects of chemotherapy and radiotherapy on spermatogenesis in humans
Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma  Jennifer L. Herrmann, Naveed Sami 
Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,
Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.
Clinical Lymphoma, Myeloma and Leukemia
Pure Erythroid Leukemia Presenting in a HIV-Positive Patient
Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors  Sean M. Parker, BS, R. Alfredo Siochi,
Autologous Stem Cell Transplantation for POEMS Syndrome
Presentation transcript:

Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis  Moussab Damlaj, Mohsen Al-Zahrani, Ghulam Syed, Giamal Gmati, Bader Alahmari, Tabrez Pasha, Ayman Alhejazi, Ahmed Alaskar  Clinical Lymphoma, Myeloma and Leukemia  Volume 19, Issue 1, Pages e71-e79 (January 2019) DOI: 10.1016/j.clml.2018.08.013 Copyright © 2018 Elsevier Inc. Terms and Conditions

Figure 1 PFS Stratified by IFI Abbreviations: IFI = interim functional imaging; Neg = negative; PFS = progression-free survival; Pos = positive. Clinical Lymphoma, Myeloma and Leukemia 2019 19, e71-e79DOI: (10.1016/j.clml.2018.08.013) Copyright © 2018 Elsevier Inc. Terms and Conditions

Figure 2 OS Stratified by IFI Abbreviations: IFI = interim functional imaging; Neg = negative; OS = overall survival; Pos = positive. Clinical Lymphoma, Myeloma and Leukemia 2019 19, e71-e79DOI: (10.1016/j.clml.2018.08.013) Copyright © 2018 Elsevier Inc. Terms and Conditions

Figure 3 PFS Stratified by Therapy and IFI Abbreviations: ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; IFI = interim functional imaging; PFS = progression-free survival. Clinical Lymphoma, Myeloma and Leukemia 2019 19, e71-e79DOI: (10.1016/j.clml.2018.08.013) Copyright © 2018 Elsevier Inc. Terms and Conditions

Figure 4 OS Stratified by Therapy and IFI Abbreviations: ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; IFI = interim functional imaging; OS = overall survival. Clinical Lymphoma, Myeloma and Leukemia 2019 19, e71-e79DOI: (10.1016/j.clml.2018.08.013) Copyright © 2018 Elsevier Inc. Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.